Home › Compare › EMMLF vs ARCC

EMMLF vs ARCC: Dividend Comparison 2026

EMMLF yields 14598.54% · ARCC yields 9.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EMMLF wins by $2315127447129181184.00M in total portfolio value
10 years
EMMLF
EMMLF
● Live price
14598.54%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2315127447129181184.00M
Annual income
$2,284,345,916,069,374,600,000,000.00
Full EMMLF calculator →
ARCC
Ares Capital Corporation
● Live price
9.06%
Share price
$21.20
Annual div
$1.92
5Y div CAGR
3.1%
Payout ratio
88%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.8K
Annual income
$2,279.31
Full ARCC calculator →

Portfolio growth — EMMLF vs ARCC

📍 EMMLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEMMLFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EMMLF + ARCC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
EMMLF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EMMLF
Annual income on $10K today (after 15% tax)
$1,240,875.91/yr
After 10yr DRIP, annual income (after tax)
$1,941,694,028,658,968,500,000,000.00/yr
ARCC
Annual income on $10K today (after 15% tax)
$769.81/yr
After 10yr DRIP, annual income (after tax)
$1,937.41/yr
At 15% tax rate, EMMLF beats the other by $1,941,694,028,658,968,500,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EMMLF + ARCC for your $10,000?

EMMLF: 50%ARCC: 50%
100% ARCC50/50100% EMMLF
Portfolio after 10yr
$1157563723564590592.00M
Annual income
$1,142,172,958,034,687,300,000,000.00/yr
Blended yield
98.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

EMMLF
No analyst data
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+3.2% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EMMLF buys
0
ARCC buys
0
No recent congressional trades found for EMMLF or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEMMLFARCC
Forward yield14598.54% ✓9.06%
Annual dividend / share$2.00 ✓$1.92
Payout ratio50% ✓88%
1-year div growth0%2% ✓
5-year div CAGR0%3.1% ✓
Portfolio after 10y$2315127447129181184.00M ✓$43.8K
Annual income after 10y$2,284,345,916,069,374,600,000,000.00 ✓$2,279.31
Total dividends collected$2313090038871241728.00M ✓$15.5K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: EMMLF vs ARCC ($10,000, DRIP)

YearEMMLF PortfolioEMMLF Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$1,470,554$1,459,854.01$11,774$933.74+$1.46M → EMMLF
2$202,208,463$200,634,970.27$13,808$1,045.61+$202.19M → EMMLF
3$25,999,823,322$25,783,460,266.67$16,135$1,166.34+$25999.81M → EMMLF
4$3,126,155,661,671$3,098,335,850,716.16$18,786$1,296.19+$3126155.64M → EMMLF
5$351,509,831,288,492$348,164,844,730,504.60$21,800$1,435.41+$351509831.27M → EMMLF
6$36,963,217,951,789,784$36,587,102,432,311,096.00$25,215$1,584.23+$36963217951.76M → EMMLF
7$3,635,193,394,947,107,000$3,595,642,751,738,691,600.00$29,076$1,742.84+$3635193394947.08M → EMMLF
8$334,373,707,794,473,750,000$330,484,050,861,880,400,000.00$33,430$1,911.44+$334373707794473.69M → EMMLF
9$28,767,786,037,201,900,000,000$28,410,006,169,861,807,000,000.00$38,328$2,090.21+$28767786037201900.00M → EMMLF
10$2,315,127,447,129,181,000,000,000$2,284,345,916,069,374,600,000,000.00$43,827$2,279.31+$2315127447129181184.00M → EMMLF

EMMLF vs ARCC: Complete Analysis 2026

EMMLF — Stock

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Full EMMLF Calculator →

ARCC — BDC

Ares Capital is the largest Business Development Company by assets. It provides financing to middle market companies and pays a generous quarterly dividend plus occasional special dividends. With $21B+ in AUM and diversified exposure across industries, ARCC is the benchmark BDC for income investors.

Full ARCC Calculator →
📬

Get this EMMLF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EMMLF vs SCHDEMMLF vs JEPIEMMLF vs OEMMLF vs KOEMMLF vs MAINEMMLF vs HTGCEMMLF vs GBDCEMMLF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.